Vyne Therapeutics Inc expected to post a loss of 17  cents a share - Earnings Preview

YARROW BIOSCIENCE

08/08/2022 18:58

* Vyne Therapeutics Inc  VYNE.OQ   VYNE.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 10
(estimated). 
    * The Bridgewater New Jersey-based  company is expected to
report 
a 97.7% decrease in revenue to $100 thousand from $4.26 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vyne Therapeutics
Inc is
for a loss of 17 cents per share. For the same quarter last
year, the company reported a loss of 35 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vyne
Therapeutics
Inc is $5​, above​ its last closing price of $0.42. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.18       -0.16      -0.14     Beat    15.2
 Dec. 31 2022  -0.20       -0.24      -0.20     Beat    15.5
 Sep. 30 2021  -0.32       -0.32      -0.36     Missed  -11.6​
 Jun. 30 2021  -0.35       -0.35      -0.35     Met     1.1
 ​​Mar.        -0.39       -0.41      -0.37     Beat    9.3
 31 2021                                                
 Dec. 31 2020  -0.53       -0.54      -0.55     Missed  -2.6​
 Sep. 30 2020  -0.68       -0.67      -0.60     Beat    10.3
 Jun. 30 2020  -0.93       -0.99      -0.80     Beat    19.5
 This summary was machine generated August 8 at 17:58 GMT.  All
figures in US dollars  unless otherwise stated